Department of Neurology, Sanjay Gandhi PGIMS, Lucknow, India.
Clin J Pain. 2009 Oct;25(8):696-8. doi: 10.1097/AJP.0b013e3181b12dd3.
Although the association of symptoms of allodynia with migraine have been reported, there is a paucity of studies on Asians.
To evaluate allodynic symptoms in migraine patients and its relationship with various clinical variables.
Consecutive migraine patients meeting the International Headache Society criteria were evaluated. Frequency, duration of illness, precipitating factors and severity of headache, associated symptoms, and functional disability were noted. Presence of allodynic symptoms and its distribution were recorded and correlated with demographic and clinical variables.
One hundred eighty-two consecutive patients with migraine without aura were included. Mean age was 30.7 years and 51 of the patients were males. Allodynic symptoms were present in 57.1%, which were triggered by various stimuli. In majority of patients, allodynic symptoms were induced by multiple stimuli. Symptoms of allodynia were restricted to the initial site of headache in 32.7%, holocranial in 46.2% and cephalic and extracephalic in 21.1% patients. Duration, frequency of migraine attacks, and functional disability were significantly associated with allodynic symptoms. Rizatriptan resulted in better relief of headache at 2 hours compared with ibuprofen in allodynic patients.
Allodynic symptoms occurred in 57.1% patients with migraine. In allodynic patients with moderate-to-severe headache, rizatriptan resulted in greater pain relief compared with ibuprofen. These results need further confirmation in larger study.
虽然已有研究报告称,痛觉过敏症状与偏头痛之间存在关联,但亚洲人群中此类研究较少。
评估偏头痛患者的痛觉过敏症状及其与各种临床变量的关系。
连续评估符合国际头痛协会标准的偏头痛患者。记录头痛的发作频率、病程、诱发因素和严重程度、伴随症状以及功能障碍。记录痛觉过敏症状的存在及其分布情况,并与人口统计学和临床变量相关联。
共纳入 182 例无先兆偏头痛患者,平均年龄为 30.7 岁,51 例患者为男性。57.1%的患者存在痛觉过敏症状,可由各种刺激诱发。多数患者的痛觉过敏症状由多种刺激诱发。痛觉过敏症状局限于初始头痛部位的患者占 32.7%,全颅性的占 46.2%,头部和头部以外部位的占 21.1%。头痛的持续时间、发作频率和功能障碍与痛觉过敏症状显著相关。与布洛芬相比,利扎曲普坦在 2 小时时可更显著缓解痛觉过敏患者的头痛。
偏头痛患者中有 57.1%存在痛觉过敏症状。在中重度头痛的痛觉过敏患者中,与布洛芬相比,利扎曲普坦可更显著缓解疼痛。这些结果需要更大规模研究进一步证实。